Manufacturing by Design
The gene therapy industry needs to reduce manufacturing costs by orders of magnitude. Let’s start by optimizing cell lines, improving transfectants, and optimizing downstream purification.
Frederic Revah | | Opinion
Thinking back as recently as 2010 and 2011, there were only a handful of organizations with serious intentions of bringing gene therapy products to the market. I remember when pharma companies and venture capitalists used to dismiss gene therapies as too complicated, risky and inefficient.
Things have certainly changed. Close to $9 billion was invested globally in cell and gene therapies in 2018. Much of this has been driven by companies focusing on rare genetic diseases, which represent a relatively straightforward target if a single gene is responsible. These first “cures” have demonstrated that gene therapies can be effective and commercially viable.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.